StageZero Life Sciences Ltd. (OTCMKTS:SZLSF) short interest fell 22.4% in September

StageZero Life Sciences Ltd. (OTCMKTS:SZLSF – Get Your Free Report ) saw a large decline in short interest during the month of September. As of September 15th, there was short interest totaling 10,400 shares, a decrease of 22.4% from August 31st’s total of 13,400 shares. Based on an average daily volume of 1,200 shares, the days-to-cover ratio is currently 8.7 days.

StageZero Life Sciences Stock Performance

Shares of StageZero Life Sciences stock remained flat at $0.15 during midday trading on Friday. The company’s 50-day simple moving average is $0.05 and its 200-day simple moving average is $0.03. StageZero Life Sciences has a 12 month low of $0.00 and a 12 month high of $1.00.

StageZero Life Sciences Company Profile

(Get a free report)

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and markets proprietary molecular diagnostic tests for early disease detection and personalized health management, with a primary focus on cancer-related indications in North America and Europe. West. Its platform’s proprietary technology is the Sentinel Principle, which identifies RNA-based biomarkers in whole blood.

Featured stories

Get news and reviews for StageZero Life Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for StageZero Life Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.